Press Releases.

- Long-Acting Parenteral Formulation of GSK2878175 Being Developed; Co-Administration with RG-101 May Enable Single Visit Therapy for HCV Patients

RG-012 Shown to Directly Inhibit microRNA-21, Demonstrates Favorable Preclinical Profile Supporting Proof of Mechanism and Clinical Development

-Phase I Clinical Data will be Featured in Viral Hepatitis Plenary Session-

-Advanced 'Clinical Map Initiative' with Start of Key Clinical Trials for RG-101 and RG-012-

-Achieves Key 'Clinical Map Initiative' Goal for 2015 and Advances Orphan Disease Efforts-

- Paul Grint, M.D. Appointed as President and Chief Executive Officer and as a Member of the Board of Directors-

- Advanced 'Clinical Map Initiative' with Positive Results on RG-101 and Selection of RG-125 as 3rd Clinical Candidate -

-RG-101 Achieves Sustained HCV Viral Suppression with Favorable Safety and Tolerability-

-Late-breaking data featured in oral presentation; three additional posters examining RG-101 pharmacokinetics, preclinical results to be presented-

-Regulus Earns $2.5 Million Milestone Payment from AstraZeneca-

- Achieved Key 2014 'Clinical Map Initiative' Goals to Advance microRNA Therapeutics Pipeline -

-Extended Follow-Up Shows 4/14 Patients Treated with a Single SC Dose of 2 mg/kg of RG-101 are Target Not Detected at Day 85 -

Accelerates RG-101 for HCV with Dual-Track Clinical Development Strategy; Top-Line, Single Dose, 4 mg/kg Results as Well as 2mg/kg Extended Follow Up Results from Ongoing Study to be Reported in Early February 2015

- Treatment with RG-012 Protects Kidney Function and Demonstrates Additive Therapeutic Effect with Emerging Standard of Care in Preclinical Model of Alport Syndrome -

- Demonstrated Human Proof-of-Concept; 'Clinical Map Initiative' Updated -

- Interim Results from Ongoing Study Demonstrate Human Proof-of-Concept and Underscore the Value of Regulus' microRNA Platform -

-New Preclinical Results Increase Mechanistic Understanding of Targeting miR-103/107 for Metabolic Disorders and miR-21 for Renal Dysfunction in Alport Syndrome Patients-

-Newly Allowed Claims Demonstrate Regulus' Leadership in the microRNA Field-

-ATHENA to Shed Light on Rare, Life-Threatening Kidney Disease -

- 'Clinical Map Initiative' On Track; Human Proof of Concept Results for RG-101 and Nomination of Third Clinical Candidate Expected by YE 2014 -

- New Method of Use Claims Strengthen Patent Estate Covering microRNA-122 Inhibitors for the Treatment of HCV Infection -

- Recognized Industry Leader Brings Extensive Clinical and Product Development Expertise -

- 'Clinical Map Initiative' On Track; Advanced RG-101 and RG-012, Expect to Nominate Third microRNA Clinical Candidate by YE 2014 -

- Data Advances microRNA Oncology Portfolio -

- Study Designed to Demonstrate Human Proof-of-Concept Results by YE 2014 -

- Achieved All Goals on 'Road to the Clinic'; Launched 'Clinical Map Initiative'-

-RG-012 is an anti-miR Targeting microRNA-21 for the Treatment of Alport Syndrome, a Life-Threatening, Genetic Kidney Disease with No Approved Therapy-

-Martin Beaulieu, Ph.D. Brings Extensive Diagnostic Assay Development Experience-

-Regulus to Develop microRNA-21 for Alport Syndrome, a Life-Threatening Orphan Kidney Disease, and microRNA-21 in Oncology, to Human Proof-of-Concept-

-Mr. Szekeres Brings Extensive Strategic and Transactional Deal Experience-

-Regulus microMarkers™ Designed to Support Regulus' Therapeutic Pipeline, its Collaborators and Strategic Partners-

- Regulatory Application for RG-101 to be Filed in the Near Term: Clinical Studies in Man Expected to Commence in Early 2014 -

- New Survival Data Presented at Kidney Week 2013 -

- Late-Breaking Poster to be Presented at AASLD -

-'Road to the Clinic' Strategy On Track; Preparing for Clinical Development of RG-101 for HCV; Second microRNA Clinical Candidate to be Nominated by Year End -

Include multimedia assets in your release for better visibility

- Nominated RG-101 in HCV as First microRNA Candidate for Clinical Development-

Industry Legend Brings Deep Biotechnology Expertise

-Progressed Partnered and Proprietary microRNA Programs-

Mr. Foletta Brings Extensive Financial and Commercial Biotechnology Expertise

-Formed Multiple Strategic Relationships to Support our microRNA-based Therapeutics and Biomarker Platforms-

Stanley T. Crooke, M.D., Ph.D. and Barry E. Greene to Step Down

-Regulus, in partnership with Sanofi, is developing novel anti-fibrotic therapies targeting microRNAs-

- Initial focus on discovery of microRNAs as biomarkers for multiple sclerosis (MS) -

Focused on three exclusive microRNA targets